Research Dosing

Cagri/Sema

🔴 IMPORTANT: Read This Before Proceeding With Dosing
Go to the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.

👉 Click here to read the Prep & Injection Guide

CagriSema (Cagrilinitide + Semaglutide)

CagriSema is a powerful combination of Cagrilinitide, a long-acting amylin analogue, and Semaglutide, a GLP-1 receptor agonist. Together, they regulate satiety, control blood sugar, and significantly reduce body weight — achieving results comparable to Tirzepatide, but through a synergistic dual mechanism.

How It Works

  • Cagrilinitide: A stabilized amylin analogue that resists enzymatic breakdown, prolonging its effects.
    • Induces satiety and reduces food intake
    • Suppresses glucagon (which raises blood sugar)
    • Slows gastric emptying, enhancing fullness
    • Promotes vasodilation, improving circulation
    • Supports bone health by reducing osteoclast activity and increasing osteoblast activity
  • Semaglutide: A GLP-1 receptor agonist that:
    • Suppresses appetite via hypothalamic signaling
    • Reduces glucagon secretion
    • Delays gastric emptying
    • Aids glucose regulation

Research-Based Benefits

  • Average 23–24.4% total body weight loss (vs. 15–17% with Semaglutide alone)
  • Comparable to weight loss achieved by Tirzepatide
  • Greater impact than using either compound individually
  • May support bone density, cardiovascular health, and glucose control

Dosing Guidelines

CagriSema: 5MG/5MG
Mix with 1.5mL (150 units) of BAC water
Subcutaneous Administration — dose weekly, on the same day each week

⚠️ Even if transferring from Semaglutide or another GLP-1, start at the lowest dose due to the potent effects of Cagrilinitide.

Week-by-Week Titration Protocol

  • Week 1–4: 5 units = 0.25mg
  • Week 5–8: 10 units = 0.5mg
  • Week 9–12: 15 units = 0.75mg
  • Week 13–16: 20 units = 1mg
  • Increase weekly as tolerated in 5-unit increments (0.25mg) until reaching:
    • 50 units = 2.5mg (maximum target dose)

Side Effects

Most are temporary and similar to other GLP-1 medications:

  • Nausea
  • Vomiting
  • Constipation or diarrhea
  • Headache
  • Abdominal discomfort
  • Injection site irritation

Contraindications

Do not use CagriSema if:

  • You have a personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN2
  • You are allergic or hypersensitive to any of its components
  • You have a history of pancreatitis
  • You are pregnant or breastfeeding
  • You are currently using another GLP-1 drug (including microdoses)

Use with caution if:

  • You have renal dysfunction
  • You have cardiovascular instability
  • You have gastroparesis or other GI motility disorders

Storage

  • Store refrigerated
  • Do not freeze
  • Shelf life: Up to 12 months when properly stored

Stacking Suggestions

  • Tirzepatide (not to be used simultaneously) – An alternative to CagriSema with similar outcomes if CagriSema causes intolerance
  • Glutathione – Supports liver detox, blood sugar balance, and reduces oxidative stress
  • Vitamin B12 or MIC+C – Enhances energy, combats fatigue, and supports fat metabolism (especially important during calorie restriction)
  • Tesofensine – May amplify appetite suppression and support dopamine-based reward pathway modulation
  • GH Secretagogues (CJC-1295 + Ipamorelin) – Preserves muscle mass and supports metabolic health during fat loss
  • Thymosin Alpha-1 – Supports immune balance in individuals with metabolic or inflammatory conditions